NGM Biopharmaceuticals Probability of Future Stock Price Finishing Under 2.38
| NGMDelisted Stock | USD 2.50 0.14 5.30% |
NGM |
NGM Biopharmaceutica Target Price Odds to finish below 2.38
The tendency of NGM Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 2.38 or more in 90 days |
| 2.50 | 90 days | 2.38 | under 4 |
Based on a normal probability distribution, the odds of NGM Biopharmaceutica to drop to $ 2.38 or more in 90 days from now is under 4 (This NGM Biopharmaceuticals probability density function shows the probability of NGM Stock to fall within a particular range of prices over 90 days) . Probability of NGM Biopharmaceuticals price to stay between $ 2.38 and its current price of $2.5 at the end of the 90-day period is roughly 2.07 .
Considering the 90-day investment horizon NGM Biopharmaceuticals has a beta of -0.18. This indicates as returns on the benchmark increase, returns on holding NGM Biopharmaceutica are expected to decrease at a much lower rate. During a bear market, however, NGM Biopharmaceuticals is likely to outperform the market. Additionally NGM Biopharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. NGM Biopharmaceutica Price Density |
| Price |
Predictive Modules for NGM Biopharmaceutica
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NGM Biopharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.NGM Biopharmaceutica Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. NGM Biopharmaceutica is not an exception. The market had few large corrections towards the NGM Biopharmaceutica's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold NGM Biopharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of NGM Biopharmaceutica within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.59 | |
β | Beta against Dow Jones | -0.18 | |
σ | Overall volatility | 0.52 | |
Ir | Information ratio | -0.15 |
NGM Biopharmaceutica Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of NGM Biopharmaceutica for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for NGM Biopharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| NGM Biopharmaceutica is not yet fully synchronised with the market data | |
| NGM Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 4.42 M. Reported Net Loss for the year was (142.38 M) with loss before taxes, overhead, and interest of (125.73 M). | |
| NGM Biopharmaceuticals has about 297.81 M in cash with (132.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
NGM Biopharmaceutica Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of NGM Stock often depends not only on the future outlook of the current and potential NGM Biopharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NGM Biopharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 82.5 M | |
| Cash And Short Term Investments | 147.2 M |
NGM Biopharmaceutica Technical Analysis
NGM Biopharmaceutica's future price can be derived by breaking down and analyzing its technical indicators over time. NGM Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of NGM Biopharmaceuticals. In general, you should focus on analyzing NGM Stock price patterns and their correlations with different microeconomic environments and drivers.
NGM Biopharmaceutica Predictive Forecast Models
NGM Biopharmaceutica's time-series forecasting models is one of many NGM Biopharmaceutica's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary NGM Biopharmaceutica's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about NGM Biopharmaceuticals
Checking the ongoing alerts about NGM Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for NGM Biopharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| NGM Biopharmaceutica is not yet fully synchronised with the market data | |
| NGM Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 4.42 M. Reported Net Loss for the year was (142.38 M) with loss before taxes, overhead, and interest of (125.73 M). | |
| NGM Biopharmaceuticals has about 297.81 M in cash with (132.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in NGM Stock
If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stocks Directory Find actively traded stocks across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Correlations Find global opportunities by holding instruments from different markets |